On December 17, the "2017 (10th) China Pharmaceutical Strategy Summit and China Pharmaceutical Industry and Commerce Joint Innovation Conference" jointly sponsored by China Pharmaceutical Industry Information Center, China Pharmaceutical Business Association, and Chongqing Biomedical Industrial Park was grandly opened in Chongqing. Nearly a thousand people from the Ministry of Industry and Information Technology, the National Health and Family Planning Commission, the State Food and Drug Administration, the Ministry of Commerce, the National Development and Reform Commission, industry associations, well-known experts and scholars in the pharmaceutical industry at home and abroad, and industry leaders participated in the event summit.
The theme of this year's summit is "linking medical industry and business, creating and sharing a new future", which is in line with the current national strategy of "Healthy China", focuses on the pharmaceutical industry pattern, development direction and path under the new situation, and connects the four major sectors of industry, learning, research and medicine. Channels, conduct in-depth exchanges and pragmatic discussions on hot spots of policies and regulations, market competition pattern, status quo and changes in various fields, and jointly promote the healthy development of the pharmaceutical industry.
At the summit, the "2017 China Pharmaceutical Industry Economic Operation Index" was also released, and the "2017 China Innovative Pharmaceutical Enterprises" list was also grandly announced. Xi'an Libang Pharmaceutical Co., Ltd. and other 20 companies won this honor. This is the third time that the company has won the list after 2015. It further demonstrates its strong innovation capabilities and R&D capabilities, and has established a good momentum of continuous, steady and rapid development.
The winning of this award is the glorious fruit of the joint efforts of all Libang people, and it is also an encouragement and spur to the company. Facing the future, Libang will continue to uphold the mission of "advocating science and bringing health to all living beings", stay true to our original aspirations, forge ahead, continue to deepen management innovation and technological innovation, and make greater contributions to China's pharmaceutical industry and human health.
Selection basis:
"China's Innovative Pharmaceutical Enterprise" is jointly selected by the Ministry of Industry and Information Technology, China Medical Information Center, and China Pharmaceutical Industry Research Institute, and comprehensively evaluates 10 dimensions of the company's innovation, layout, potential, operation, and strategy.
The selection of "China's Innovative Pharmaceutical Enterprises" is a rigorous, scientific, and authoritative selection of innovation in my country's pharmaceutical industry, and it is also an important basis for adding points or quality grading references in drug bidding in some provinces.
Background introduction:
The China Pharmaceutical Strategy Summit has attracted many enterprises to share the latest innovations and innovative management practices. It plays an active role in promoting the integration of "industry, research, research and medicine" and the transformation of scientific and technological achievements, promoting technical cooperation and promoting the integration of industry and finance. Provide strategic consulting for enterprise transformation and upgrading, predict industry trends, and integrate professional high-end summits with insightful vision.
On the morning of February 27, Zhang Xiaoning, Secretary of the Party Leadership Group and Director of the Shaanxi Provincial Food and Drug Administration, led a group of 5 people in Lu Qiang, Director of the Xi'an Food and Drug Administration, Li Dayue, Deputy Inspector, Shen Siqing, Director of the Pharmaceutical Production Supervision Department, Yanta District Accompanied by Zhang Huajun, director of the Food and Drug Administration, he visited Xi'an Libang Pharmaceutical Co., Ltd. located on the Science and Technology Road of Xi'an High-tech Zone to carry out research activities. Libang Medical Industry Group President Ju Jianbo, Vice President Hui Minquan, Libang Pharmaceutical Factory Director Hu Huali and other leaders accompanied them.
During the symposium, Mr. Ju extended a warm welcome to all the leaders for their visit, and expressed his sincere thanks to the governments at all levels for their support, care and help to Libang over the years! The company profile, main business, product introduction, economic operation, quality management, future outlook and other aspects are introduced in detail.
The research team listened to the report and learned more about the difficulties and problems encountered in the company's current development process. Director Zhang expressed his support for Libang to build an FDA export base in Northwest China and made it clear that the provincial and municipal bureaus will give active help; at the same time, he emphasized that experts will be organized to study in time for the difficulties, problems and related suggestions of enterprises, and the provincial and municipal bureaus will help enterprises to coordinate as soon as possible solve.
Subsequently, Director Zhang and his party visited the production workshop, inquired about the production management and quality management in detail, and gave affirmation. Hu Huali introduced the layout, quality management, production process, etc., and focused on the company's investment in the production automation of Limengxin Injection and Libangxitong Injection in recent years and the achievements in improving production efficiency.
The company will take this survey as an opportunity to continue to make three good drugs with "good curative effect, good quality and good service", continuously improve the GMP management level, strictly control the quality, create more high-quality products, and devote itself to continuously improving product technology and innovation ability, gradually realize the beautiful goals of the enterprise, and make new contributions to the cause of human health.
On June 19, Meng Jianzhu, former member of the 18th Central Political Bureau and former secretary of the Central Political and Legal Committee, visited the Libang Pharmaceutical Research Institute located in the High-tech Zone Entrepreneurship R&D Park. Ju Jianbo, President of Libang Medical Industry Group, and Libang Chen Tao, dean of the Institute of Medicine, accompanied the visit.
During the period, Meng Jianzhu and his party visited the laboratory and analysis center of Libang Research Institute, and had a cordial conversation with everyone. Ju Jianbo, president of Libang Medical Industry Group, and Chen Tao, president of Libang Pharmaceutical Research Institute, gave detailed introductions on the company's main products, enterprise development status, and new drug research and development.
At the same time, I learned about the company's key products: propofol emulsion injection, alprostadil injection, medium and long-chain fat emulsion injection and the medical device "non-invasive instantaneous continuous blood pressure monitor", and personally tried the newly developed smart glove wearer "Qiaoshou" affirmed the innovative ideas of this product.
Finally, the visiting group unanimously affirmed Libang's achievements in new drug research and development, and encouraged Libang to further explore new development paths for the R&D industry under the influence of a series of new national policies to encourage innovation, so as to achieve faster and better development of the enterprise.
background introduction
Libang Pharmaceutical Research Institute is the scientific research management organization of Xi'an Libang Medical Industry Group Co., Ltd., one of the "Top 100 Pharmaceutical Enterprises". Pharmaceutical Co., Ltd. Research Institute, Xi'an Libang Biomedical Technology Co., Ltd., and Beijing Libang Biomedical Technology Co., Ltd. five scientific research companies. Since its establishment in 2016, it has been equipped with modern instruments and equipment in line with international standards. Relying on independent innovation of science and technology, it has built an innovative drug technology platform, covering all aspects of drug development such as early drug discovery, preclinical research, and pilot production. The successful transformation of research and development into the platform continuously enhances the ability of independent research and development and innovation, and helps Libang Medical Industry Group to achieve new breakthroughs.
Lu Zhiyuan, vice governor of Shaanxi Province, and his party visited Xi'an Libang Pharmaceutical Co., Ltd. for investigation
On July 3, Lu Zhiyuan, vice governor of Shaanxi Province, and his entourage visited Libang Pharmaceutical for in-depth investigation, and learned about the company's production and operation, scientific and technological research and development, and the development of intelligent manufacturing. Zhang Xiaoning, director of Shaanxi Food and Drug Administration, and Lu Qiang, director of Xi'an Food and Drug Administration, accompanied the delegation. Li Tan, chairman of Libang Pharmaceutical, Ju Jianbo, president of Libang Medical Industry Group, Hui Minquan, general manager of Libang Pharmaceutical, and Hu Huali, director of Libang Pharmaceutical, accompanied them.
During the meeting, Ju Jianbo extended a warm welcome to all the leaders for their visit, and expressed his sincere thanks to the governments at all levels for their support, care and help to Libang over the years! A brief introduction was made from the aspects of enterprise production and operation, innovation and development, personnel training and strategic planning.
During the period, Lu Zhiyuan and his party visited the production workshop, inquired about the production management and quality management in detail, and had a cordial conversation with everyone. Hu Huali introduced the layout, quality management, production process, etc., and focused on the company's investment in the production automation of Limengxin Injection and Libangxitong Injection in recent years and the achievements in improving production efficiency.
Finally, Lu Zhiyuan and his party fully affirmed the achievements of Libang Pharmaceutical in all aspects. Libang Pharmaceutical has strong stamina and a good development trend, and should be supported as a key enterprise in Shaanxi Province. It also stated that 20 million yuan of policy funding support will be given to a class of new drugs developed, and 3 million yuan of policy funding support will be given to drugs that have passed the consistency evaluation of generic drugs. At the same time, relevant provincial departments are required to create a better policy environment to support enterprises to become bigger and stronger. I hope that Libang will continue to build its core competitiveness and enter the era of tens of billions of revenue as soon as possible.
The company will take this survey as an opportunity to continue to make three good drugs with "good curative effect, good quality and good service", continuously improve the GMP management level, strictly control the quality, create more high-quality products, and devote itself to continuously improving product technology and innovation ability, gradually realize the beautiful goals of the enterprise, and make new contributions to the cause of human health.
